Conventional plasmids for gene therapy produce low-level and short-term gene expression. Here, we first created minicircle carrying endostatin (mc-hES) for measurement of transfection efficiency. Compared with pcDNA-hES, MC-mediated endostatin gene transfer in vitro resulted in seven-fold greater endostatin expression levels in transfected cells and inhibited the growth of Human umbilical vein endothelial cells (HUVEC) more efficiently. HUVEC cell migration and tube-formation assays suggested that MC-mediated endostatin gene has significant anti-migration and anti-tube-formation capacity than that in pcDNA-hES. In vivo experiments showed that after transfection, mc-hES inhibited the growth of nasopharyngeal carcinoma xenografts. The tumor inhibition rates of mc-hES and pcDNA-hES were 60.8% and 26.9%, respectively (Po0.05). MC-mediated intratumoral endostatin expression in vivo was 2.2-17.9 times higher than pcDNA-hES in xenografted mice and lasted for 20 days. Our results suggest that minicircle DNA vectors might be a promising vector for biotherapy and should be further investigated.
Introduction
Nasopharyngeal carcinoma (NPC) is a highly malignant disease of the head and neck. It occurs at an unusually high frequency in the Chinese population in Southeast Asia. Although NPC is a radiosensitive tumor, only 10-40% of cases presenting with advanced disease survive 5 years. 1, 2 Moreover, once metastasis has developed, 85% of patients die within 1 year. 2, 3 It is therefore necessary to develop additional forms of treatment for NPC. Malignant tumor growth, invasion and distant metastasis depend on neoangiogenesis. Endostatin is an angiogenesis inhibitor tested in multiple clinical trials that selectively targets neovascular endothelial cells. It has little toxicity or side effects and repeated delivery does not lead to drug resistance. [4] [5] [6] [7] For these reasons, gene therapy with endogenous antiangiogenic genes represents an appropriate therapeutic strategy.
There are two strategies to provide target genes for gene transfer: viral-based and nonviral-based systems. 8 Their ability to integrate DNA sequences into host chromosomes enables therapeutic genes to permanently remain in transduced cells. However, such integrating vectors still suffer from transcriptional silencing, 9 host immune responses, 10, 11 transient transgene expression and potential tumorigenesis. 12 Moreover, rapid transgene silencing of traditional plasmids is often observed, even in nondividing tissue culture cells.
Minicircle DNA is an excellent vector for non-viral gene therapy. It is created by the removal of plasmid backbone DNA through intramolecular site-specific recombination within a minicircle producer plasmid. It can be engineered to contain predominantly human sequences with a low incidence of immunostimulatory CpG-containing motifs. [13] [14] [15] It has been demonstrated that transgenes carried by minicircle DNA vectors have persistently high levels of expression in mouse liver and tumor tissues. [16] [17] [18] [19] Here we investigate the possibility of a MC-endostatin-based therapy.
Materials and methods

Plasmid and cells
Plasmid p2jC31 (9. 7 kb) was a kind gift from Dr Zhiying Chen (Stanford University, Stanford, CA). 20 pSP72 was obtained from Promega (Madison, WI, USA). Plasmid pSP72-hEndostatin-IRES-EGFP (4.5 kb) carrying the human endostatin expression cassette, which follows an IL-2 signal sequence was constructed by our lab. HUVEC were a kind gift from Dr Saiwah Tsao (University of Hong Kong, China). HepG2 (liver cancer cell line) and CNE-2 (poorly-differentiated NPC cell line, EBV negative) cells were kept by our lab.
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Plasmid construction and production of mc-hES The plasmid p2jc31 included XhoI and SpeI cloning sites. pSP72-Pcmv-BGHpolyA was generated by inserting Pcmv (cytomegalovirus promoter) and BGHpolyA (bovine growth factor polyadenylation signal), which were amplified from the plasmid pcDNA3.1 by PCR into pSP72. Then, we inserted the BamHI/BglII-hEndo-IRES-EGFP-SalI fragment from pSP72-hEndo-IRES-EGFP into pSP72-Pcmv-BGHpolyA and pcDNA3.1( þ ), respectively, resulting in pSP72-Pcmv-hEndo-IRES-EGFP-BGHpolyA (pSP72-hES) and a positive control plasmid, pcDNA-hES. The NheI-Pcmv-hEndostatin-IRES-EGFP-BGHpolyAXhoI fragment from pSP72-hES was inserted into p2jc31, yielding the pj-hES. Minicircle carrying endostatin (Mc-hES) was produced as described previously. 8, 21 Overnight bacterial growth from a single colony of plasmidtransformed Escherichia coli Top 10 in Tris-borate medium was centrifuged at 20 1C, 4000 r.p.m. for 20 min. The pellet was resuspended 4:1 (v/v) in fresh Luria-Bertani broth containing 1.5% L-arabinose. The bacteria were incubated at 32 1C with constant shaking at 250 r.p.m. for 2 h. After adding one-half volume of fresh Luria-Bertani broth (pH 8.0) containing 1% L-arabinose, the incubation temperature was increased to 37 1C and the incubation continued for an additional 2 h. Episomal DNA circles were prepared from bacteria using plasmid purification kits from Qiagen (Chatsworth, CA).
Expression of human endostatin in eukaryotic cells
Three cell lines were studied: HUVEC, HepG2 and CNE-2. Experiments were carried out in the log phase of growth. HepG2 and CNE-2 cells were maintained at 37 1C in a 5% CO 2 incubator with RPMI 1640 containing 100 units ml À1 penicillin, 100 mg ml À1 streptomycin plus 10% fetal bovine serum (Gibco, Paisley, UK). HUVEC were maintained in Ham's F12K with 0.1 mg ml
À1
Heparin, 4 ng ml À1 basic fibroblast growth factor, 0.05 mg ml À1 endothelial cell growth supplement (ECGS) and 10% fetal bovine serum.
Cells were seeded at a density of 5 Â 10 5 cells per well in 6-well flat-bottom microassay plates 24 h before transfection. At 60-70% confluence, cells were transfected with 5 mg of pj-hES, an equimolar 2.9 mg of pcDNA-hES or equimolar 1.3 mg of mc-hES and incubated for an additional 72 h. This treatment regimen was used to transfect cells with the same ratio of Lipofectamine 2000 (Life Technologies, Invitrogen) to DNA in each case (1.5:1). Lipofectamine 2000 was used for the transfection according to the manufacturer's protocol.
We evaluated EGFP expression by fluorescence microscopy and then CNE-2 cells were harvested for assessment of endostatin expression, 72 hours after transfection. Cells were lysed with lysis buffer (50 mM Tris-HCl (pH 7.6), 1% Brij35, 0.14 M NaCl, 1 mM MgCl 2 , 1 mM MnCl 2 , 1 mM phenylmethylsulfonyl fluoride and one tablet per 50 ml of proteinase inhibitor cocktail without EDTA). 10 mg of cell lysate was used for western blot.
RNA preparation and reverse transcription-PCR Total RNA was prepared using Trizol (Life Technologies, Gaithersburg, MD) as described by the manufacturer. 1 mg aliquots were used for reverse transcription with reverse transcription system (Promega). PCR reactions were done using the following primers: mouse b-actin, 
Activity assay of endostatin produced by mc-hES transfected cells
The effect of endostatin on endothelial cell proliferation was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. CNE-2 cell supernatants were harvested as conditioned medium (CM) after 72 h of transfection and endostatin expression was evaluated using a human endostatin ELISA kit (R&D systems, Minneapolis, MN) according to the recommendation of the manufacturer. 3000 HUVECs were dispensed in each well of a 96-well culture plate. After allowing for attachment overnight, an array of HUVECs containing quadruplicate sets of cultures was treated with endostatin for 30 min. After 72 h we aspirated the supernatant, added 100 ml MTT (1 mg ml À1 ) to each well, continued incubation for 4 h at 37 1C, reaspirated the supernatant, added 0.1 ml dimethyl sulfoxide to each well, shook for 10 min and then read the absorbance (A) at 490 nm. Inhibition ratio ¼ (control group's AÀsample group's A) Â 100%/control group's A. CM from p2jC31 served as a negative control. In the proliferation assay, after cells were plated overnight, the medium was replaced with 50 ml of CM. Thirty minutes later HUVECs CM (150 ml) was added.
Tube formation assay HUVECs (10 000 per well) were suspended in 25 ml of CM and gently added to matrigel-coated wells in 96-well plates. Thirty minutes later, 75 ml of HUVECs CM containing 20 ng ml À1 vascular endothelial growth factor (Peprotech, London, UK) was added. After 16 h, images were captured under Â 50 magnification and tube formation was scored as follows: a three-branch-point event was scored as one tube.
Boyden chamber assay
Transwell inserts with 8-mm-pore size (Costar, MD, USA) were coated with 0.78 mg ml À1 matrigel (Becton Dickinson, Bedford, MA). Harvested HUVECs (20 000 per well) were preincubated with CM for 30 min before 150 ml of serum-free Ham's F12K was added to the upper chamber of the inserts and 500 ml complete medium containing 50 ng ml À1 vascular endothelial growth factor was added to the lower wells. After 6 h of incubation, the upper surface of the insert was swabbed to remove nonmigrated cells. HUVECs were fixed by cold 70% ethanol and fluorescently stained with DAPI (Roche Molecular Biochemicals, Mannheim, Germany). Cell migration was quantitated by counting the number of migrated cells under Â 100 magnification with a DMIRB Leica fluorescence microscope (Leica Microsystems, Wetzlar, Germany).
Effect of mc-hES treatment on the growth of NPC xenografts
The Ethical Committee of the Sun-yat Sen University Cancer Center approved the study. All animals used in this study were treated humanely and the experiments were carried out strictly following the protocols approved by the Institutional Animal Care and Use Committee of Guangdong Province.
BALB/c nude mice (4-6-week-old, weight 20-23 g, license no. 26-2004A009) were purchased from the Experimental Animal Center, Sun Yat-sen University and maintained in a specific pathogen-free environment.
For antitumor experiments, a total of 25 mice were used for xenograft models. 2 Â 10 6 CNE-2 cells were injected subcutaneously into the right flank of 6-week-old BALB/c nude mice. When B150 mm 3 tumors had formed, mice were randomly assigned to five groups; each group had five animals. These groups were injected intratumorally with a DNA mixture once a week as follows: 21 mg mc-hES, equimolar 80 mg of pj-hES, equimolar 50 mg pcDNA-hES, equimolar 50 mg empty vector p2jc31 and an equal volume of 0.9% NaCl solution as a negative control. All animals were treated for 3 weeks. Mice were weighed and tumors were monitored in two diameters with digital calipers. Tumor volume was calculated by the formula:
/2 (L, length; W, width). Upon termination of the experiment the tumors were removed. The inhibition rate of each treated group was determined according to tumor weight.
For intratumoral expression analysis mice were also treated with mc-hES or pcDNA-hES at the same dose as described previously, except for the injection frequency. The treated mice received just one injection during 3 weeks. A total of 48 mice were used for xenograft model (12 mice per group). Three mice for each time point were tested. Tumor tissue samples were harvested on days 3, 7, 14 and 20 post-injection of mc-hES and pcDNA-hES. Tumors were excised and fixed in either RNA later or were snap frozen. Endostatin levels were determined using a human ELISA kit (R&D Systems, Inc.,) according to the manufacturer's instructions.
Immunohistology
To investigate whether the antitumor effect is associated with a reduction in tumor angiogenesis, immunohistology was used to assess the profile of CD31-positive microvessel density by vessels. After experiments were completed, tumors were excised and fixed in 4% paraformaldehyde and embedded in paraffin. Paraffinembedded tissue sections were incubated with rabbit antimouse CD31 (Neomarkers, Lab Vision, CA) and the sections were visualized with DAB using DAKO Envision system (Dako, Carpinteria, CA).
Statistical analysis
Results were evaluated using t-test and one-way analysis of variance with SPSS 11.0 software (SPSS, Inc., Chicago, IL), unless otherwise specified. Po0.05 was considered statistically significant.
Results
Construction of plasmid and mc-hES
We constructed pcDNA-hES and pj-hES successfully, and mc-hES can be produced by intramolecular recombination. The details of this construction are given in Materials and methods. Mc-hES has the following components: the endostatin gene, immediate-early human cytomegalovirus promoter and bovine growth factor polyadenylation signal. All constructs were confirmed by restriction enzyme digestion and DNA sequencing (Figure 1 ).
Production by transfected cell lines
Green fluorescence was observed under a fluorescence microscope 72 hours after transfection. Greater hyperfluorescence was observed in the mc-hES group than in the pcDNA-hES and pj-hES groups. Endostatin was also found to be more highly expressed in the mc-hES group than in the pcDNA-hES or pj-hES groups by RT-PCR and western blot analysis (Figure 2a and b) . No endostatin was found in the culture medium from p2jc31 transfected cells. A similar result was obtained in HepG2 and HUVEC cells (data not shown).
Endostatin gene transfer inhibits the proliferation of HUVEC The expression levels of endostatin in CM-mc-hES, CMpcDNA-hES and CM-pj-hES were 197.9±25.2, 39.1 ± 8.6 and 17.4 ± 3.4 ng ml
À1
, respectively. We found that incubation of HUVECs with CM-pcDNA-hES and CM-pj-hES inhibited proliferation at the rate of 16.5% and 13.7%, respectively, compared with the CM-p2jC31 control. CM-mc-hES appeared to have a higher antiproliferative rate of 43.5% on HUVECs than CMpcDNA-hES and CM-pj-hES (Po0.05, Figure 2d ).
Inhibition of HUVECs migration and tube formation
Control CM-p2jc31-HUVECs grown on matrigel aligned to form tube-like structures over 16 h and connected tubes with multicentric junctions. pcDNA-hES and pj-hES inhibited tube formation by 31.6% and 27.5%, respectively (Figure 2e ), compared with the control. However, mc-hES inhibited tube formation to a greater extent (57.4%, Po0.01).
Stimulation of HUVECs along a directional gradient of vascular endothelial growth factor resulted in migration to the underside of the insert. The migration of HUVECs treated with CM-pcDNA-hES or pj-hES was significantly reduced by 50.8% and 43.4%, respectively (Figure 2f ). But mc-hES showed a stronger inhibitory effect on HUVEC migration (68.9%, Po0.05), compared with CM-pcDNA-hES or pj-hES.
Nonviral gene transfer of endostatin inhibits human NPC xenografts growth
For antitumor experiments, CNE-2 cell-xenografted mice were observed for 20 days. Tumor volumes were recorded to assess the antitumor effects of these treatment groups. The tumors in the saline group and the p2jc31 group increased gradually after administration. The growth of tumors in the pcDNA-hES group was lagging in the 7 days after administration and then increased gradually. Notably, in the mc-hES group, the tumor growth was stunted up to the end of the experiment. The growth of tumors after mc-hES treatment was significantly slower than those in the pcDNA-hES and control groups (Figure 3a) . No significant differences in the growth of tumors of pcDNA-hES and two negative control groups were observed (P40.05). The inhibition rates of mc-hES, pj-hES and pcDNA-hES were 60.8%, 24.7% and 26.9%, respectively. The weight of tumors after mc-hES or pcDNA-hES treatment was significantly less than those of the control groups (Po0.05). But the mc-hES group showed more profound antitumor potential than the pcDNA-hES-treated and pj-hES-treated group (Po0.05; Figure 3b ). All of the treatments were tolerated well, and no difference in animal behaviour or weight was found between groups in tumor models.
Inhibition of tumor neovascularization
To investigate whether the antitumor effect is associated with a reduction in the tumor angiogenesis, micro-vascular density (MVD) was determined by CD31-positive cells per Â 200 field. There was no significant difference between the saline and p2jc31 groups in terms of MVD in tumor of mice, but there was a significant difference between the mc-hES and pcDNA-hES groups (15.0±3.5 versus 25.8 ± 6.1, Po0.05, Figure 3c and 
d).
Dynamic expression in vivo of human endostatin gene delivered by minicircle and pcDNA3. 1 The expression of endostatin protein and transcript can be detected from day 3 to day 20 in the mc-hES group after one injection. But in the pcDNA-hES group, it was detectable on day 3 then decreased sharply and was barely detectable on day 7 and undetectable on day 14. No endostatin protein or transcript was found in the empty p2jc31 group or untreated tumors (Figure 4a and b) . In addition, endostatin expression in the mc-hES group was 2.2-17.9 times higher than that in the pcDNA-hES group.
Discussion
Plasmid DNA was utilized in roughly 25% of all clinical gene therapy trials as of mid 2007. 23 Standard plasmid vectors are composed of a transgene expression cassette and plasmid bacterial backbone (BB) DNA. In our study, we used the I-sceI site, a jc31 recombinase temperature-sensitive recognition, and a cutting site to exclude the plasmid BB and degrade the BB. After isolation from the BB, the MC carries only short bacterial sequences. 8 We chose the minicircle system to develop a minicircle DNA vector carrying the human endostatin gene. In vitro, mc-hES has significant transgene expression compared with pj-hES and pcDNA-hES. mc-hES(3.1 kb)o pcDNA-hES(7.5 kb)o pj-hES (12.9 kb), but the transfection efficiency is inversely proportional to size. These results are concordant with a scenario in which the smaller the plasmid size and more the copies of the plasmid, the more stable and higher is the transfection efficiency. It demonstrates that under the same conditions, minicircle vectors have obvious merits compared with their precursors and traditional eukaryotic expression plasmids. In vivo experiments demonstrated that both mc-hES and pcDNA-hES inhibited the growth of xenografted tumors. In antitumor experiments, in the first 7 days, no significant difference in tumor volume was observed between the mc-hES and pcDNA-hES group; later the difference became gradually significant. In the minicircle group, because the expression of endostatin was stable and lasting, the antitumor effect was permanent after administration. This is consistent with the levels of transgene expression in the tumor tissues and the velocity of tumor growth. This agrees with the reports of Huang et al. 8 and Wu et al. 21 The episomal transgene is silenced when there is a covalent connection of plasmid BB DNA sequences to the expression cassette. 24 In particular, the BB sequences are riddled with CpG islands, which can lead to transcriptional gene silencing in vivo. This is one of the major reasons why regular plasmids are notoriously ineffective for long-term expression 18, 24 and is the main limiting factor for the clinical application of plasmids. Otherwise, there was a progressive time-dependent reduction of endostatin levels even in the minicircle group. This may be associated with the high turnover rate of tumor cells. 21, 25 Endostatin is an angiogenesis inhibitor that has been tested in multiple clinical trials. It is expected to reduce intratumoral microvessel formation, limiting the supply of blood reaching the tumor mass and thereby suppressing tumor growth. In recent research, endostatin labeled with a near-infrared probe was shown to selectively accumulate in the tumor site. 26 Furthermore, it specifically binds to neovascular endothelial cells through its interaction with the integrin receptors aVb1 and aVb3.
27,28 aVb3 has been implicated in tumor metastasis. Endothelial cells are attractive drug targets because they are considered to be genetically stable and are less likely to become drug resistant.
Our results suggest that mc-hES yields a higher level of transgene expression than conventional plasmids both in vitro and in vivo. In summary, taking advantage of the minicircle to deliver endostatin may potentially be a new therapeutic strategy in the field of NPC gene therapy.
